Harmony Biosciences (HRMY) reported Q1 adjusted earnings Tuesday of $1.03 per diluted share, up from $0.88 a year earlier.
Four analysts polled by FactSet expected $0.83.
Revenue for the quarter ended March 31 was $184.7 million, compared with $154.6 million a year earlier.
Analysts surveyed by FactSet expected $182.3 million.
For 2025, the company said it continues to expect revenue of $820 million to $860 million.
Analysts polled by FactSet expect $840.4 million.
The company's shares were up more than 3.5% in recent Tuesday premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.